The ASCPT 2024 Annual Meeting will be held as an in-person event March 27-29, at the Broadmoor in Colorado Springs, CO. Registrants for the meeting will enjoy three days filled with professional development, networking, and the latest research in clinical pharmacology and translational science. Reunite and reconnect with friends and colleagues face-to-face in Colorado Springs!

MEETING DATES AND LOCATION
Dates: March 27-29, 2024
Location: The Broadmoor, Colorado Springs, CO.

The hotel reservation deadline for the Broadmoor was March 6, 2024, and the ASCPT housing block is now full. ASCPT has secured a housing block at the Cheyenne Mountain Resort. The Cheyenne is located just two miles from the Broadmoor and ASCPT will be providing shuttle service between these hotels. Although the housing deadline at the Cheyenne was March 4, 2024, reservations are being taken based on availability and may not be the special ASCPT Annual Meeting rate. Please use the link below to secure your sleeping room at the ASCPT discounted rate.

Cheyenne Mountain: https://book.passkey.com/e/50770385

Questions about housing may be directed to meetings@ascpt.org.

PRE-CONFERENCE PROGRAMS
Enjoy an extra day of science! Prior to the official start of the Annual Meeting, ASCPT will be offering two Pre-Conference Sessions on Tuesday, March 26. Please note that Pre-Conference Sessions are not included in the Full Conference registration and must be registered for separately.

Pre-Conference Session: Empowering Clinical Pharmacologists and Translational Scientists Using Artificial Intelligence: Unlocking Potential with Cutting-Edge Use Cases: Tuesday, March 26, 2024, 8:30 AM- 5:30 PM

For many years, clinical pharmacologists have been using mathematical models to represent physiological processes and explore the relationships between drugs and changes in PK/PD over time. The rapid advancements in imaging, diagnostics, computing, and communication technologies have created a vast data landscape that clinical pharmacologists now need to navigate.

While various Artificial Intelligence (AI) techniques have proven to be powerful computational approaches in other datarich fields, their application in clinical pharmacology is still in its early stages. Implementing AI in clinical pharmacology and translational science holds the potential to develop more effective therapies and address patients’ unmet clinical needs more efficiently and quickly. Demonstrating successful case studies and best practices of AI use by clinical pharmacologists and translational scientists is crucial for broader adoption in these fields, both regionally and globally.

This Pre-Conference will showcase different aspects of AI used in clinical pharmacology and translational science, including cutting-edge AI tools, commonly used data sources, and successful case studies and applications. We will feature interdisciplinary teams presenting how AI has improved prediction models in both clinical settings and drug development. Additionally, this Pre-Conference will explore the potential opportunities of using large language models like ChatGPT and other medical foundational models to establish a better paradigm for incorporating AI in clinical pharmacology and drug development.

Pre-Conference Session: Clinical Trial Diversity & Inclusion: How Clinical Pharmacology Can Support the Implementation of Regulatory Guidance on Diversity Plans: Tuesday, March 26, 2024, 8:30 AM- 5:30 PM

In a recent FDA draft guidance (April 2022), the FDA recommends that sponsors developing investigational medical products enroll an adequate number of trial participants from under-represented populations and prepare a diversity plan. Generating a diversity plan in early clinical development can be a challenging task as safety and tolerability of investigational products across diverse populations is not fully established.

In this pre-conference, experts from industry, academia, IQ, and regulators will discuss how to utilize clinical pharmacology tools in drug development to implement the guidance and generate diversity plans. Case study presentations will demonstrate how clinical pharmacology concepts can be used to increase enrollment of under-represented populations in clinical trials by enhanced understanding of the disposition of molecules, performing risk assessments using M&S (determine restrictions on concomitant medications or in organ impairment), developing well-designed clinical trials (e.g. inclusion of Asian cohort in Phase 1 study), and applying technologies to enable DCT. An interactive workshop session will reinforce the key learning points of the presentations and case studies.